Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: FP29-Adrenal Tumors & Pheochromocytoma
Monday, June 17, 2013: 10:45 AM-11:15 AM
Presentation Start Time: 10:50 AM
Room 134 (Moscone Center)

Poster Board MON-2
Michaela Luconi1, Pamela Pinzani1, Cristian Scatena2, Francesca Salvianti1, Elisa Corsini1, Letizia Canu1, Giada Poli1, Valentina Piccini1, Gabriella Nesi2 and Massimo Mannelli*1
1University of Florence, Florence, Italy, 2University of Florence
OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare malignancy, the prognosis of which mainly depends on stage at diagnosis. The identification of disease-associated markers representing solid biomarkers for early diagnosis and drug monitoring is mandatory to improve survival rate and life quality of patients. CTC are tumor cells originating from primary tumor or metastases. The tumor-induced angiogenesis and invasion allow aggressive tumors to release CTC into blood stream before any detectable metastases are established. Therefore, CTC detection may have enormous potential of assisting malignancy diagnosis, estimating prognosis and monitoring the disease. The presence of CTC in ACC patients have never been investigated so far.

DESIGN & METHODS: CTC  analysis was performed in 14 ACC and 10 adrenocortical adenoma (ACA) patients. Blood samples obtained before (n=3 patients) and after (n=10 patients) surgery were filtered on Screencell devices (Screencell®), polycarbonate membranes with 8 µm pores, which isolate CTC  on size-basis.

RESULTS: CTC were isolated in all ACC but not in ACA samples. Immunocytochemistry on CTC, compared to the primary tumors, revealed positivity for adrenocortical markers, confirming the adrenocortical origin. When ACC patients were stratified in two classes according to the cut-off of the median value of the clinical parameters (tumor diameter, Ki67, Weiss) or to the presence/absence of metastasis, a statistically significant difference was found in the number of post-surgical CTC only when diameter (CTC/ml mean±SD: 2.70±3.70 vs 0.59±0.67, P=0.028 for diameter>/=8 and<8cm, respectively) and metastatic stage (CTC/ml mean±SD: 3.91±4.83 vs 0.70±0.70, P=0.031, for stage=4 versus the others, respectively) were  considered

CONCLUSIONS: Our findings provide the first evidence that circulating tumor cells (CTC) may represent  a valid and useful marker to support diagnosis in adrenocortical tumor pathologies. Moreover, CTC  seem to correlate with some clinical parameters. Although very preliminary, these results, which need confirmation in larger series, suggest a potential use of this so-called “liquid biopsy” for prognosis and non-invasive monitoring progression and response to treatments.

Nothing to Disclose: ML, PP, CS, FS, EC, LC, GP, VP, GN, MM

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

Sources of Research Support: Seventh Framework Programme (FP7/2007-2013) grant agreement n° 259735 ENS@T-Cancer;   FIRB fund of the Italian Minister of University, Research and Instruction (prot number: RBAP1153LS)